Vincenzo Maria Romeo

Prof. Dr. Vincenzo Maria Romeo

Culture and Society, University of Palermo, Palermo, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
UMUmberto Micò
Umberto Micò
GSGiuseppe Scimeca
Giuseppe Scimeca
RZRocco A. Zoccali
Rocco A. Zoccali
Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, the present 16-week, double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of aripiprazole add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients receiving SRIs. After clinical and neurocognitive assessments, patients were randomly allocated to receive, in a double-blind design, 15 mg/d of aripiprazole or a placebo. A final sample of 30 patients completed the study. The results obtained indicate that aripiprazole added to stable SRI treatment substantially improved obsessive-compulsive symptoms as measured by changes on the Yale-Brown Obsessive Compulsive Scale total score and subscores (obsessions, P = 0.007; compulsions, P = 0.001; total score, P < 0.0001). Regarding cognitive functions, improvement was observed in some explored areas, such as attentional resistance to interference (Stroop score, P = 0.001) and executive functioning (perseverative errors, P = 0.015). The findings provide evidence that aripiprazole augmentation of SRIs/clomipramine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.

3 September 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
GMGiovanni Martinotti
Giovanni Martinotti
MAMaria Chiara Alessi
Maria Chiara Alessi
CNChiara Di Natale
Chiara Di Natale
ASAntonella Sociali
Antonella Sociali
FCFranca Ceci
Franca Ceci
MGMassimo di Giannantonio
Massimo di Giannantonio
Background: Following the development of the COVID-19 pandemic, a rigid public health strategy of reduced social contact and shelter-in-place has been adopted by the Italian Government to reduce the spread of the virus. In this paper, we aim at evaluating the impact that the COVID-19 pandemic, and the relative containment measures, have had on a real-life sample of patients suffering from substance use disorders (SUDs) and/or behavioral addictions. Methods: An anonymous questionnaire was filled out by 153 addicted patients, both outpatients and residential inpatients, recruited across Italy and highly representative of the current Italian population suffering from addictions. Psychopathological burden (anxiety and depressive symptomatology, somatization, irritability, and post-traumatic symptoms), quality of life, and craving changes in daily habits were assessed. Results: In our sample, we found moderate rates of depression (22.9%), anxiety (30.1%), irritability (31.6%), and post-traumatic stress (5.4%) symptoms. Psychopathological burden was globally higher among residential patients. Reported levels of craving were generally low. Discussion: This study is the first attempt to collect Italian data regarding the effects of the rigid quarantine period, during the COVID-19 pandemic, on patients suffering from a SUD and/or behavioral addictions. The presence of a moderate psychopathological burden correlated to poor quality of life and low craving scores represented the main outcomes. Long-term studies, with follow-up after the end of the restrictive measures, should be considered to implement our findings.

28 October 2014 in Journal of Addiction
Verified
Journal Article
Open access
PDF file
Antonio BrunoAntonio Bruno
Antonio Bruno
DQDiego Quattrone
Diego Quattrone
GSGiuseppe Scimeca
Giuseppe Scimeca
CCClaudio Cicciarelli
Claudio Cicciarelli
Vincenzo Maria RomeoVincenzo Maria Romeo
Vincenzo Maria Romeo
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
The aim of this study was to assess the risk of exercise addiction (EA) in fitness clubs and to identify possible factors in the development of the disorder. The Exercise Addiction Inventory (EAI), the Narcissistic Personality Inventory (NPI), and the Coopersmith Self-Esteem Inventory (SEI) were administered to a sample of 150 consecutive gym attenders recruited in fitness centers. Based on EAI total score, high EA risk group (HEAn=51) and a low EA risk group (LEAn=69) were identified. HEA reported significantly higher total score (mean = 20.2 versus 14.6) on the NPI scale and lower total score (mean = 32.2 versus 36.4) on the SEI scale than LEA. A stepwise regression analysis indicated that only narcissism and self-esteem total scores (F=5.66;  df=2;  P=0.006)were good predictors of days per week exercise. The present study confirms the direct and combined role of both labile self-esteem and high narcissism in the development of exercise addiction as predictive factors towards the risk of addiction. Multidisciplinary trained health care providers (physiatrists, psychologists, and psychiatrists) should carefully identify potential overexercise conditions in order to prevent the potential risk of exercise addiction.

1 November 2011 in International Clinical Psychopharmacology
Verified
Journal Article
Closed access
UMUmberto Mico’
Umberto Mico’
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
Vincenzo Maria RomeoVincenzo Maria Romeo
Vincenzo Maria Romeo
DMDomenico Mallamace
Domenico Mallamace
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antidepressant drugs have often been used as an augmentation strategy for those patients who have demonstrated a suboptimal response to clozapine. The present 16-week double-blind, randomized, placebo-controlled trial study aimed to explore the efficacy and tolerability of duloxetine add-on pharmacotherapy on clinical symptomatology and executive cognitive functioning in a sample of patients with treatment-resistant schizophrenia receiving clozapine. After clinical and neurocognitive assessments, the patients were randomly allocated to receive, in a double-blind design, at a dose of 60 mg per day of duloxetine or a placebo. A final sample of 33 patients completed the study. The results obtained indicate that duloxetine added to stable clozapine treatment showed a beneficial effect on the negative and general psychopathological symptomatology in a sample of treatment-resistant schizophrenic patients. With regard to executive cognitive functions, duloxetine augmentation of clozapine had no significant effects. The findings provide evidence that duloxetine augmentation of clozapine treatment is safe and well tolerated and may be of benefit for patients who are partially responsive to clozapine monotherapy.

25 September 2012 in Archives of Sexual Behavior
Verified
Journal Article
Closed access
PDF file
GSGiuseppe Scimeca
Giuseppe Scimeca
Antonio BrunoAntonio Bruno
Antonio Bruno
GPGianluca Pandolfo
Gianluca Pandolfo
UMUmberto Micò
Umberto Micò
Vincenzo Maria RomeoVincenzo Maria Romeo
Vincenzo Maria Romeo
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello

1 October 2008 in International Journal of Law and Psychiatry
Verified
Journal Article
Closed access
RZR. Zoccali
R. Zoccali
Maria Rosaria Anna MuscatelloMaria Rosaria Anna Muscatello
Maria Rosaria Anna Muscatello
Antonio BrunoAntonio Bruno
Antonio Bruno
RCR. Cambria
R. Cambria
LCL. Cavallaro
L. Cavallaro
MMM. Meduri
M. Meduri